Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Current Liabilities: 2012-2025

Historic Total Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $74.8 million.

  • Agios Pharmaceuticals' Total Current Liabilities fell 37.42% to $74.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.8 million, marking a year-over-year decrease of 37.42%. This contributed to the annual value of $81.2 million for FY2024, which is 19.43% up from last year.
  • Agios Pharmaceuticals' Total Current Liabilities amounted to $74.8 million in Q3 2025, which was up 6.17% from $70.4 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Total Current Liabilities' 5-year high stood at $119.5 million during Q3 2024, with a 5-year trough of $45.1 million in Q1 2023.
  • In the last 3 years, Agios Pharmaceuticals' Total Current Liabilities had a median value of $62.6 million in 2024 and averaged $67.2 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 52.55% in 2022, then soared by 104.45% in 2024.
  • Agios Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $59.8 million in 2021, then increased by 4.69% to $62.6 million in 2022, then grew by 8.50% to $68.0 million in 2023, then grew by 19.43% to $81.2 million in 2024, then plummeted by 37.42% to $74.8 million in 2025.
  • Its Total Current Liabilities was $74.8 million in Q3 2025, compared to $70.4 million in Q2 2025 and $52.4 million in Q1 2025.